Actively Recruiting
Evaluating a Modified Ublituximab Regimen for Relapsing Multiple Sclerosis Safety, Efficacy, and Pharmacokinetics Assessment
Led by TG Therapeutics, Inc. · Updated on 2026-10-23
800
Participants Needed
51
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a modified regimen of ublituximab for adults with relapsing multiple sclerosis RMS in this phase 3b study. The study aims to assess the medicines impact on brain lesions visible on MRI scans and its pharmacokinetics, particularly in participants who had limited benefit from prior anti-CD20 therapies. The trial includes three parts Part A is open-label and single-arm, Part B is randomized, double-blind, and placebo-controlled, and Part C is open-label and single-arm. Participants receive ublituximab through intravenous infusions, with dosing schedules varying by study part. In Part A, infusions occur on Day 1 of Week 1, Day 15 if applicable, and at Week 24. In Part B, participants receive either 600 mg ublituximab on Week 1 Day 1, placebo on Day 15, and 450 mg ublituximab at Week 24, or 150 mg ublituximab on Week 1 Day 1 followed by 450 mg on Day 15 and Week 24. Part C participants receive 150 mg on Week 1 Day 1 and 450 mg on Day 15 and Week 24. During the study, participants are monitored for changes in T1 Gadolinium-enhancing lesions on MRI from baseline to Week 48, infusion-related reactions, treatment satisfaction, and pharmacokinetics over 16 weeks. Safety and efficacy assessments include neurological stability, clinical exams, and questionnaires. The total study duration extends to at least 48 weeks, with detailed follow-up and monitoring to evaluate treatment impact and participant health.
CONDITIONS
Brief Title
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Research Team
T
TG Therapeutics Clinical Support Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here